Middle East & AfricaDrug Modelling Software Market Growth and Recent Trends by 2027

The Middle East & Africadrug modelling softwaremarketis expected to reach US$ 297.94 million by 2027 from US$ 487.02 million in 2019; it is estimated to grow at a CAGR of 6.6% from 2020 to 2027.

Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.

The discovery and development of new drugs with potential therapeutic applications is a complex, expensive, and time-consuming venture. Considering this challenge, many novel technologies have been developed to increase the efficiency of the drug discovery process. Computational methodologies have become a crucial part of several drug discovery programs. From hit identification to lead optimization, techniques such as ligand or structure-based virtual screening are widely being used by many pharmaceutical companies. With the help of modelling, existing data can be leveraged to gain insights on product safety and effectiveness. Nowadays, In-Silico design (computer-aided) is being utilized to expedite and facilitate hit identification, optimize the absorption, distribution, metabolism, and toxicity profile to avoid safety issues. Commonly used in-silico approaches include ligand-based drug design, structure-based drug design, and quantitative structure-activity.

Moreover, various pharmaceutical companies have started adopting these techniques for better outcomes. Large Indian pharmaceutical firms have taken different routes toward “innovative drug discovery”. The mode is to set up in-house “NCE discovery units”, which serve as the innovation engine. A variation of this theme is to establish biotech-like drug discovery units outside the country and drive discovery and development through this collaborative medium. These approaches have seen steady increase in the number of compounds in clinical development.  Moreover, many research organizations have also started adopting drug modelling technologies for expediting the research process. For instance, NYU Abu Dhabi researchers design new technology for targeted cancer drug delivery. A team of researchers at NYU Abu Dhabi has developed a biocompatible, biodegradable, and economical nanocarrier for safer and more effective delivery of anticancer drugs. Researchers demonstrate that the novel pH-responsive hybrid (i.e. multi-component) nanoparticles can be loaded with a wide range of chemotherapeutics to effectively and specifically target cancer cells, as reported in their paper published on March 3, 2020, in the journal Communications Biology. Thus, above mentioned factors are expected to drive the growth of the drug modelling software market during the forecast period.

The countries in this region are sequencing complete COVID-19 genome. For instance, a new initiative to study and identify genetic factors that cause symptoms of the coronavirus disease (COVID-19) among Saudis has been launched in Riyadh, as part of the Kingdom’s efforts to tackle the pandemic. The initiative will help in developing national genetic databases in cooperation with the health sector and developing solutions and strategic plans to protect the population of the Kingdom and those most at risk of contracting the disease, in addition to increasing the efficiency of current treatment methods and the development of new drugs. Thus, continuous research on COVID-19 using drug discovery platforms is expected to fuel the growth of the market.

Rest of Middle East & AfricaDrug Modelling Software Market,Revenue and Forecast to 2027 (US$ Mn)

MIDDLE EAST & AFRICADRUG MODELLING SOFTWARE MARKET SEGMENTATION

By Product Type

• Database
• Software
• Others

By Application

• Drug Discovery and Development
• Computational Physiological Medicine
• Disease Modeling
• Medical Imaging
• Predictive Analysis of Drug Targets
• Simulation Software
• Cellular Simulation
• Others

By Country

• Saudi Arabia
• South Africa
• UAE
• Rest of Middle East & Africa

Company Profiles

• Crown Bioscience Inc (JSR life science)
• Compugen Ltd.
• Biognos AB
• Dassault Systèmes
• Acellera

Middle East & AfricaDrug Modelling Software Report Scope